<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576653</url>
  </required_header>
  <id_info>
    <org_study_id>23-343</org_study_id>
    <nct_id>NCT01576653</nct_id>
  </id_info>
  <brief_title>Prospective Clinical Evaluation of Beta-D-Glucan Assay in Blood and BAL</brief_title>
  <official_title>Prospective Clinical Evaluation of Bata-D-Glucan Assay for Diagnosis of Invasive Fungal Infection in Blood and Bronchoalveolar Lavage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert Krause, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with invasive fungal infection (IFI) rapid diagnosis is essential for early&#xD;
      initiation of appropriate antifungal therapy and thereby survival. Conventional culture is&#xD;
      still the Gold-Standard for diagnosis of IFI. Sensitivity of conventional culture, however,&#xD;
      is low (50%) and time to results minimum 24 hours.&#xD;
&#xD;
      Therefore usage of serological tests detecting fungal antigens has increased dramatically&#xD;
      over recent years. Main advantages of this new methods are rapid results and higher&#xD;
      sensitivity when compared to conventional culture. One of the most promising serological&#xD;
      marker currently used is beta-D-Glucan, which is a component of the fungal cell wall.&#xD;
      ß-D-Glucan has been detected in IFI caused by Aspergillus, Candida and Fusarium spp. The&#xD;
      Fungitell Assay (Associates of Cape Code, Inc.) was developed and validated for detection of&#xD;
      ß-D-Glucan in peripheral blood.&#xD;
&#xD;
      Up to date information about clinical performance of the Fungitell Assays in bronchoalveolar&#xD;
      lavage fluid (BAL) is limited. This study will therefore evaluate clinical and diagnostic&#xD;
      performance of the Fungitell Assay in BAL from patients with solid organ transplant or&#xD;
      hematologic malignancy.&#xD;
&#xD;
      In addition Mn/A-Mn, the lateral flow device test for aspergillosis, and Galactomannan, as&#xD;
      well as PCR will be determined and used as comparators for BDG performance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2011</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fungitell Assay from BAL in patients with hematologic malignancy or ICU patients/patients after solid organ transplantation and suspected IFI</measure>
    <time_frame>6 months after intervention</time_frame>
    <description>Diagnostic potential of Fungitell Assay from BAL in patients with hematologic malignancy or ICU patients/ patients after solid organ transplantation and suspected IFI</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Invasive Fungal Infection</condition>
  <condition>Hematological Malignancy</condition>
  <condition>Receipt of Solid Organ Transplant</condition>
  <arm_group>
    <arm_group_label>No IFI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do not fulfill EORTC/MSG IFI criteria will serve as negative controls.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IFI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do fulfill EORTC/MSG criteria of possible/probable/proven IFI will serve as study group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fungitell Assay in BAL</intervention_name>
    <description>Fungitell Assay will be performed in BAL from patients with clinical suspicion of IFI</description>
    <arm_group_label>IFI</arm_group_label>
    <arm_group_label>No IFI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  above 18 years of age&#xD;
&#xD;
          -  Bronchoscopy performed in clinical routine due to suspicion of IFI&#xD;
&#xD;
          -  Hematological malignancy or receipt of solid organ transplant/ICU&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  below 18 years of age&#xD;
&#xD;
          -  No bronchoscopy performed&#xD;
&#xD;
          -  No Hematological malignancy nor receipt of solid organ transplant/ICU&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 10, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Graz</investigator_affiliation>
    <investigator_full_name>Robert Krause, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>IFI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

